APS-2-79
目录号 : GC15240
An inhibitor of KSR-dependent MAPK signaling
Cas No.:2002381-31-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Cell viability assays are performed in 96 well plates. Optimal cell densities for 96 well plate assays are determined to obtain linear growth over the time course of assays. A549, HCT-116, A375, SK-MEL-239, COLO-205, LOVO, SK-MEL-2, CALU-6, MEWO, SW620 and SW1417 cells are plated at 500 cells per well and treated with inhibitors (e.g., APS-2-79; 100-3,000 nM) for 72hrs before measuring viability. H2087 and HEPG2 cells are plated at 2000 cells per well, and treated with inhibitors (e.g., APS-2-79; 100-3,000 nM) for 72hrs. Cell viability is measured using Resazurin, and the percent cell viability is determined by normalizing inhibitor-treated samples to DMSO controls[1]. |
References: [1]. Dhawan NS, et al. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature. 2016 Aug 24;537(7618):112-116. | |
IC50: 120 nM
APS-2-79 is a KSR-dependent MAPK modulator.
Kinase suppressor of Ras (KSR), a MAPK scaffold, is subject to allosteric regulation via dimerization with RAF. Targeting of KSR has important therapeutic implications for cancer, however, testing this hypothesis is difficult due to the lack of small-molecule KSR antagonists.
In vitro: APS-2-79 was found to be able to suppress KSR-stimulated MEK and ERK phosphorylation. This MAPK signalling suppression caused by APS-2-79 was dependent on direct targeting of KSR as an active site mutant, which had been demonstrated to stimulate KSR-based MAPK outputs independent of ATP-binding, which could significantly diminish the activity of APS-2-79. Moreover, the KSR-stimulated MEK phosphorylation caused by RAF was reduced by the addition of APS-2-79 markedly. In addition, APS-2-79 was no effetive when KSR was absent or when the KSR2(A690F) mutant was used for in vitro assays, indicating that the activity of APS-2-79 was from direct targeting of KSR. However, APS-2-79 was found to lack direct activity against the highly homologous active RAF family kinases, such as recombinant BRAF and CRAF, or cellular BRAF(V600E) [1].
In vivo: So far, there is no animal in vivo data reported.
Clinical trial: Up to now, APS-2-79 is still in the preclinical development stage.
Reference:
[1] Dhawan NS, Scopton AP, Dar AC. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature. 2016 Sep 1;537(7618):112-116.
| Cas No. | 2002381-31-7 | SDF | |
| 化学名 | 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine hydrochloride | ||
| Canonical SMILES | CC1=CC(OC2=CC=CC=C2)=CC=C1NC3=C4C=C(OC)C(OC)=CC4=NC=N3.[H]Cl | ||
| 分子式 | C23H22ClN3O3 | 分子量 | 423.89 |
| 溶解度 | DMF: 10 mg/mL,DMSO: 25 mg/mL,DMSO:PBS (pH 7.2) (1:2): 0.3 mg/mL,Ethanol: 1 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3591 mL | 11.7955 mL | 23.591 mL |
| 5 mM | 0.4718 mL | 2.3591 mL | 4.7182 mL |
| 10 mM | 0.2359 mL | 1.1796 mL | 2.3591 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。